A multi-faCtorial, mulTi-arm, multi-staGe, randomised, gLOBal Adaptive pLatform trial for stroke

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2026/009

Enrollment

Unknown

Registered

2026-04-01

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

The study setting/ Study sites: Only the NTERACT5 Domain will be conducted in Sri Lanka. Study sites: Sri Jayewardenepura General Hospital, National Hospital of Sri Lanka, Kandy National Hospital, N

Eligibility

Inclusion criteria

Inclusion criteria: Platform Inclusion Criteria: 1. Age equal or greater than 18 years 2. Clinical diagnosis of stroke

Exclusion criteria

Exclusion criteria: Each state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfil the overall platform criteria will be assessed for enrollment into each active domain.

Design outcomes

Primary

Measure	Time frame
Modified Rankin scale (mRS) scores [Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)]	—

Secondary

Measure	Time frame
Excellent functional neurological outcome [Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)] Independent functional neurological outcome [Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)] Health Related Quality of Life [ Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)] Mortality [ Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; State and Domain specific time frame may differ (details will be included in domain-specific registration)]	—

Measure

Time frame

Excellent functional neurological outcome [Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)] Independent functional neurological outcome [Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)] Health Related Quality of Life [ Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)] Mortality [ Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; State and Domain specific time frame may differ (details will be included in domain-specific registration)]

—

Countries

Sri Lanka

Contacts

Public ContactDr. Harsha Hemal Gunasekara

Consultant Neurologist

hemalhg@gmail.com07189488587

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 10, 2026